HK52196A - Use of omeprazole as an antimicrobial agent - Google Patents

Use of omeprazole as an antimicrobial agent

Info

Publication number
HK52196A
HK52196A HK52196A HK52196A HK52196A HK 52196 A HK52196 A HK 52196A HK 52196 A HK52196 A HK 52196A HK 52196 A HK52196 A HK 52196A HK 52196 A HK52196 A HK 52196A
Authority
HK
Hong Kong
Prior art keywords
pct
omeprazole
antimicrobial agent
methoxy
sec
Prior art date
Application number
HK52196A
Other languages
English (en)
Inventor
Masaaki Tomoi
Yoshifumi Ikeda
Yoshiko Yokota
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12300238&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK52196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of HK52196A publication Critical patent/HK52196A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK52196A 1989-02-09 1996-03-21 Use of omeprazole as an antimicrobial agent HK52196A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1030311A JP2694361B2 (ja) 1989-02-09 1989-02-09 抗菌剤
PCT/SE1990/000070 WO1990009175A1 (en) 1989-02-09 1990-02-02 Use of omeprazole as an antimicrobial agent

Publications (1)

Publication Number Publication Date
HK52196A true HK52196A (en) 1996-03-29

Family

ID=12300238

Family Applications (1)

Application Number Title Priority Date Filing Date
HK52196A HK52196A (en) 1989-02-09 1996-03-21 Use of omeprazole as an antimicrobial agent

Country Status (19)

Country Link
US (1) US5093342A (ko)
EP (1) EP0414847B1 (ko)
JP (1) JP2694361B2 (ko)
KR (1) KR0140236B1 (ko)
AT (1) ATE94063T1 (ko)
AU (1) AU626641B2 (ko)
CA (1) CA2025668C (ko)
CY (1) CY1909A (ko)
DE (1) DE69003207T2 (ko)
DK (1) DK0414847T3 (ko)
ES (1) ES2058892T3 (ko)
HK (1) HK52196A (ko)
HU (1) HU205253B (ko)
IE (1) IE65814B1 (ko)
IL (1) IL93263A0 (ko)
LV (1) LV10577B (ko)
MY (1) MY111737A (ko)
PH (1) PH26787A (ko)
WO (1) WO1990009175A1 (ko)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114114T1 (de) * 1989-02-10 1994-12-15 Takeda Chemical Industries Ltd Verwendung von benzimidazol-derivaten als antibakterielle mittel.
GB9018603D0 (en) * 1990-08-24 1990-10-10 Smith Kline French Lab Compositions
WO1992004898A1 (de) * 1990-09-14 1992-04-02 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachten erkrankungen
TW276996B (ko) * 1992-04-24 1996-06-01 Astra Ab
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0673246A1 (de) * 1992-12-10 1995-09-27 Byk Gulden Lomberg Chemische Fabrik GmbH Verwendung von alkylthiopyridinen zur bekämpfung von heliobacter-bakterien
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
AU4596796A (en) * 1995-02-07 1996-08-27 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU751066B2 (en) * 1997-12-08 2002-08-08 Nycomed Gmbh Novel administration form comprising an acid-labile active compound
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
WO1999036422A1 (en) 1998-01-14 1999-07-22 The Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US20030129186A1 (en) 2001-07-25 2003-07-10 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
EP1603537A4 (en) * 2003-02-20 2009-11-04 Santarus Inc IMMEDIATE RELEASE OF OMEPRAZOLE ANTACIDAL COMPLEX WITH NEW FORMULATION FOR RAPID AND PROLONGED ELIMINATION OF GASTRIC ACID
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
SI2003130T1 (sl) 2006-03-10 2012-02-29 Arigen Pharmaceuticals Inc Nov piridinski derivat, ki ima aktivnost proti Helicobacter pylori
EP2063905B1 (en) 2006-09-18 2014-07-30 Raptor Pharmaceutical Inc Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2667682A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
SI2103608T1 (sl) 2006-12-18 2012-12-31 Arigen Pharmaceuticals, Inc. Sredstvo za eradikacijo Helicobacterja pylori z inhibitorno aktivnostjo za izločanje želoldčne kisline
DK2398500T3 (da) 2009-02-20 2019-05-13 2 Bbb Medicines B V Glutathion-baseret lægemiddelafgivelsessystem
US20120041030A1 (en) 2009-04-09 2012-02-16 Masaichi Yamamoto Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action
ES2942923T3 (es) 2009-05-06 2023-06-07 Laboratory Skin Care Inc Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas
US8722026B2 (en) * 2010-01-06 2014-05-13 Elc Management, Llc Skin lightening compositions
US8992897B2 (en) 2010-01-06 2015-03-31 Elc Management Llc Skin lightening compositions
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
KR101628474B1 (ko) * 2014-08-27 2016-06-08 경북대학교 산학협력단 오메프라졸을 유효성분으로 포함하는 피부 미백용 화장료 조성물
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
WO1989003829A1 (en) * 1987-10-30 1989-05-05 Aktiebolaget Hässle Omeprazole for treatment of diseases related to bone loss

Also Published As

Publication number Publication date
IE65814B1 (en) 1995-11-15
DK0414847T3 (da) 1993-12-13
ATE94063T1 (de) 1993-09-15
LV10577B (en) 1995-10-20
AU626641B2 (en) 1992-08-06
CA2025668C (en) 1998-09-15
CA2025668A1 (en) 1990-08-10
HU901539D0 (en) 1991-02-28
DE69003207T2 (de) 1994-02-03
IE900418L (en) 1990-08-09
EP0414847A1 (en) 1991-03-06
US5093342A (en) 1992-03-03
JP2694361B2 (ja) 1997-12-24
HUT54890A (en) 1991-04-29
HU205253B (en) 1992-04-28
JPH02209809A (ja) 1990-08-21
MY111737A (en) 2000-12-30
EP0414847B1 (en) 1993-09-08
WO1990009175A1 (en) 1990-08-23
IL93263A0 (en) 1990-11-29
AU5038190A (en) 1990-09-05
KR910700048A (ko) 1991-03-13
DE69003207D1 (de) 1993-10-14
CY1909A (en) 1990-02-02
ES2058892T3 (es) 1994-11-01
PH26787A (en) 1992-10-13
LV10577A (lv) 1995-04-20
KR0140236B1 (ko) 1998-06-01

Similar Documents

Publication Publication Date Title
CY1909A (en) Use of omeprazole as an antimicrobial agent
UA32524C2 (uk) Спосіб одержання омепразолу
CA2274076A1 (en) Crystalline form of s-omeprazole
AR103295A2 (es) Compuesto cristalino de benzimidazol, composición farmacéutica que lo comprende y método para la manufactura de dicha composición
ES2195345T3 (es) Nueva forma de s-omeprazol.
NO1995005I1 (no) Omeprazole/ 5-metoksy-2-[[(4-metoksy-3,5-dimetyl-2-pyridinyl)metyl]sulfinyl]-1H-benzimidazol
HUT62882A (en) Process for producing dialkoxy pyridylmethyl sulfinyl benzimidazole derivatives and pharmaceutical compositions comprising same
AR013350A1 (es) Sal de sodio de omeprazol forma b, proceso para su preparacion, formulacion farmaceutica, y uso de dicha sal para la fabricacion de medicamentos.
IS1854B (is) Aðferð til að útbúa ljósfræðilega hrein Na+, Mg2+, Li+, K+ eða Ca2+ sölt (-)-5-metoxý-2-[[(4-metoxý-3,5-dímetýl-2-pýridínýl)metýl]súlfinýl]-1H-bensimídasóls og milliefnasamband.
TR200101282T2 (tr) Omeprozolün yeni kristalli formu
PL246492A1 (en) Process for preparing novel salts of 5-methoxy-2-(/(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl/ sulfinyl)-1h-benzimidazole
ZA989999B (en) New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole
HU901085D0 (en) Process for producing substituted benzimidazole and pharmaceutical preparatives containing it
NO974969L (no) Multimer rekombinant ureasevaksine
GR3024058T3 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
NO964252D0 (no) Anvendelsen av spiramycin for behandling av gastrointestinale mangler som forårsaket av H.pylori
IT1271434B (it) Composizione farmaceutica avente attivita' antiasmatica

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090202